In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides

International Journal of Antimicrobial Agents

Volumn 34, Issue 4, 2009, Pages 309-314

  Kanthawong, Sakawrat ^a,b   Nazmi, Kamran ^c   Wongratanacheewin, Surasakdi ^a,b   Bolscher, Jan G M ^c   Wuthiekanun, Vanaporn ^d   Taweechaisupapong, Suwimol ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antimicrobial peptides; Burkholderia pseudomallei; Histatins; Lactoferrin; LL 37

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAZIDIME; COTRIMOXAZOLE; HISTATIN 5; LACTOFERRIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; MELIOIDOSIS; MORTALITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THAILAND;

AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BURKHOLDERIA PSEUDOMALLEI; HISTATINS; HUMANS; LACTOFERRIN; LIPOPOLYSACCHARIDES; MELIOIDOSIS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; SOIL MICROBIOLOGY;

EID: 67651225112     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.05.012     Document Type: Article

References (50)

1. Cheng A.C., and Currie B.J. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18 (2005) 383-416
2. White N.J. Melioidosis. Lancet 361 (2003) 1715-1722
3. Rajchanuvong A., Chaowagul W., Suputtamongkol Y., Smith M.D., Dance D.A., and White N.J. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 89 (1995) 546-549
4. Suputtamongkol Y., Dance D.A., Chaowagul W., Wattanagoon Y., Wuthiekanun V., and White N.J. Amoxycillin-clavulanic acid treatment of melioidosis. Trans R Soc Trop Med Hyg 85 (1991) 672-675
5. Thibault F.M., Hernandez E., Vidal D.R., Girardet M., and Cavallo J.D. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54 (2004) 1134-1138
6. Jenney A.W., Lum G., Fisher D.A., and Currie B.J. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17 (2001) 109-113
7. Dance D.A.B., Wuthiekanun V., Chaowagul W., Suputtamongkol Y., and White N.J. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J Antimicrob Chemother 28 (1991) 321-324
8. Minassian M.A., Gage A., Price E., and Sefton A.M. Imipenem for the treatment of melioidosis. Int J Antimicrob Agents 12 (1999) 263-265
9. Cheng A.C., Fisher D.A., Anstey N.M., Stephens D.P., Jacups S.P., and Currie B.J. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 48 (2004) 1763-1765
10. Wiersinga W.J., van der Poll T., White N.J., Day N.P., and Peacock S.J. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 4 (2006) 272-282
11. Sexton M.M., Goebel L.A., Godfrey A.J., Choawagul W., White N.J., and Woods D.E. Ribotype analysis of Pseudomonas pseudomallei isolates. J Clin Microbiol 31 (1993) 238-243
12. Mookherjee N., and Hancock R.E.W. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 64 (2007) 922-933
13. Oudhoff M.J., Bolscher J.G.M., Nazmi K., Kalay H., van't Hof W., Nieuw Amerongen A.V., et al. Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay. FASEB J 22 (2008) 3805-3812
14. Niyonsaba F., Ushio H., Nagaoka I., Okumura K., and Ogawa H. The human β-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 175 (2005) 1776-1784
15. Reddy K.V., Yedery R.D., and Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 24 (2004) 536-547
16. Gough M., Hancock R.E., and Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 64 (1996) 4922-4927
17. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
18. Axen A., Carlsson A., Engstrom A., and Bennich H. Gloverin, an antibacterial protein from the immune hemolymph of Hyalophora pupae. Eur J Biochem 247 (1997) 614-619
19. Groisman E.A. Bacterial responses to host-defense peptides. Trends Microbiol 4 (1996) 127-128
20. Boman H.G., Agerberth B., and Boman A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun 61 (1993) 2978-2984
21. Park C.B., Kim H.S., and Kim S.C. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244 (1998) 253-257
22. Leem J.Y., Nishimura C., Kurata S., Shimada I., Kobayashi A., and Natori S. Purification and characterization of N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine, a novel antibacterial substance of Sarcophaga peregrina (flesh fly). J Biol Chem 271 (1996) 13573-13577
23. Den Hertog A.L., Wong Fong Sang H.W., Kraayenhof R., Bolscher J.G., Van't Hof W., Veerman E.C., et al. Interactions of histatin 5 and histatin 5-derived peptides with liposome membranes: surface effects, translocation and permeabilization. Biochem J 379 (2004) 665-672
24. Den Hertog A.L., van Marle J., van Veen H.A., Van't Hof W., Bolscher J.G., Veerman E.C., et al. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J 388 (2005) 689-695
25. Stallmann H.P., Faber C., Bronckers A.L., de Blieck-Hogervorst J.M., Brouwer C.P., Amerongen A.V., et al. Histatin and lactoferrin derived peptides: antimicrobial properties and effects on mammalian cells. Peptides 26 (2005) 2355-2359
26. Van der Kraan M.I., Groenink J., Nazmi K., Veerman E.C., Bolscher J.G., and Nieuw Amerongen A.V. Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25 (2004) 177-183
27. Van der Kraan M.I., van der Made C., Nazmi K., van't Hof W., Groenink J., Veerman E.C., et al. Effect of amino acid substitutions on the candidacidal activity of LFampin 265-284. Peptides 26 (2005) 2093-2097
28. Anuntagool N., Naigowit P., Petkanchanapong V., Aramsri P., Panichakul T., and Sirisinha S. Monoclonal antibody-based rapid identification of Burkholderia pseudomallei in blood culture fluid from patients with community-acquired septicaemia. J Med Microbiol 49 (2000) 1075-1078
29. Wuthiekanun V., Smith M.D., Dance D.A., Walsh A.L., Pitt T.L., and White N.J. Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. J Med Microbiol 45 (1996) 408-412
30. Wuthiekanun V., Anuntagool N., White N.J., and Sirisinha S. Short report: a rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis. Am J Trop Med Hyg 66 (2002) 759-761
31. Anuntagool N., Wuthiekanun V., White N.J., Currie B.J., Sermswan R.W., Wongratanacheewin S., et al. Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. Am J Trop Med Hyg 74 (2006) 348-352
32. Taweechaisupapong S., Kaewpa C., Arunyanart C., Kanla P., Homchampa P., Sirisinha S., et al. Virulence of Burkholderia pseudomallei does not correlate with biofilm formation. Microb Pathog 39 (2005) 77-85
33. Godfrey A.J., Wong S., Dance D.A., Chaowagul W., and Bryan L.E. Pseudomonas pseudomallei resistance to β-lactam antibiotics due to alterations in the chromosomally encoded β-lactamase. Antimicrob Agents Chemother 35 (1991) 1635-1640
34. Smith M.D., Wuthiekanun V., Walsh A.L., and White N.J. In-vitro activity of carbapenem antibiotics against β-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother 37 (1996) 611-615
35. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically, approved standard. Document M7-A5. Wayne, PA: NCCLS, 2000.
36. Turner J., Cho Y., Dinh N.N., Waring A.J., and Lehrer R.I. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42 (1998) 2206-2214
37. Golec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. Ann Agric Environ Med 14 (2007) 1-4
38. Johansson J., Gudmundsson G.H., Rottenberg M.E., Berndt K.D., and Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273 (1998) 3718-3724
39. Vorland L.H. Lactoferrin: a multifunctional glycoprotein. APMIS 107 (1999) 971-981
40. Hwang P.M., Zhou N., Shan X., Arrowsmith C.H., and Vogel H.J. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37 (1998) 4288-4298
41. Van der Kraan M.I., Nazmi K., van't Hof W., Amerongen A.V., Veerman E.C., and Bolscher J.G. Distinct bactericidal activities of bovine lactoferrin peptides LFampin 268-284 and LFampin 265-284: Asp-Leu-Ile makes a difference. Biochem Cell Biol 84 (2006) 358-362
42. Macfarlane E.L., Kwasnicka A., and Hancock R.E. Role of Pseudomonas aeruginosa PhoP-phoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146 (2000) 2543-2554
43. Kawasaki K., China K., and Nishijima M. Release of the lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to the antimicrobial peptide polymyxin B in Salmonella enterica. J Bacteriol 189 (2007) 4911-4919
44. White N.J., Dance D.A., Chaowagul W., Wattanagoon Y., Wuthiekanun V., and Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 2 (1989) 697-701
45. Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111 (2003) 1665-1672
46. Shaykhiev R., Beisswenger C., Kandler K., Senske J., Puchner A., Damm T., et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 289 (2005) L842-L848
47. Ciornei C.D., Egesten A., and Bodelsson M. Effects of human cathelicidin antimicrobial peptide LL-37 on lipopolysaccharide-induced nitric oxide release from rat aorta in vitro. Acta Anaesthesiol Scand 47 (2003) 213-220
48. De Smet K., and Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27 (2005) 1337-1347
49. Cirioni O., Giacometti A., Ghiselli R., Bergnach C., Orlando F., Silvestri C., et al. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 50 (2006) 1672-1679
50. Wiersinga W.J., Wieland C.W., van der Windt G.J., de Boer A., Florquin S., Dondorp A., et al. Endogenous interleukin-18 improves the early antimicrobial host response in severe melioidosis. Infect Immun 75 (2007) 3739-3746